Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Melanoma Cells
100%
Personalized Therapy
100%
Genetic Parameters
100%
Uveal Melanoma Cells
100%
RAF Kinase
100%
Akt Kinase
100%
PLX4720
100%
MEK Kinase
100%
AZD6244
85%
Mutant Cells
71%
Uveal Melanoma
57%
BRAF mutant
42%
Genotype
28%
MEK Inhibitor (MEKi)
28%
BRAF mutation
28%
BRAF Inhibitor (BRAFi)
28%
MK-2206
28%
GNA11
28%
Clinical Trials
14%
Apoptosis
14%
Immunoblot Analysis
14%
Patient Selection
14%
Metastatic Melanoma
14%
Effective Therapy
14%
ERK Phosphorylation
14%
Cell Apoptosis
14%
Cell Cycle Arrest
14%
G Protein
14%
Mutually Exclusive
14%
Targeted Therapy
14%
Patient's Will
14%
Somatic mutation
14%
G Protein Subunit
14%
Apoptosis Assay
14%
Melanoma Patients
14%
Design Selection
14%
Cell Viability Assay
14%
Cell Proliferation Assay
14%
B-Raf
14%
Synergistic Therapy
14%
Protein mutations
14%
Medicine and Dentistry
Uvea Melanoma
100%
Protein Kinase B
100%
Personalized Medicine
100%
B Raf Kinase
100%
Uveal Melanoma Cell Line
100%
N [3 (5 Chloro 1h pyrrolo[2,3 B]pyridine 3 Carbonyl) 2,4 Difluorophenyl]propanesulfonamide
87%
Selumetinib
75%
Cell Mutant
62%
Melanoma Cell
50%
Guanine Nucleotide Binding Protein
25%
MEK Inhibitor
25%
Protein Kinase B Inhibitor
25%
8 [4 (1 Aminocyclobutyl)phenyl] 9 Phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) One
25%
Clinical Trial
12%
Immunoblotting
12%
Programmed Cell Death
12%
Patient Selection
12%
Targeted Therapy
12%
Cell Cycle Checkpoint
12%
Cell Cycle Arrest
12%
Melanoma Skin Cancer
12%
Antineoplastic Activity
12%
Hexachlorophene
12%
Kinase
12%
Somatic Mutation
12%
Protein Subunit
12%
Apoptosis Assay
12%
Cell Viability Assay
12%
Protein Kinase B
12%
Biochemistry, Genetics and Molecular Biology
Genotyping
100%
Cell Mutant
100%
Protein Kinase B
100%
Raf Kinase
100%
Protein Kinase B
60%
G Protein
40%
MEK Inhibitor
40%
GNA11
40%
GNAQ
40%
Clinical Trial
20%
Programmed Cell Death
20%
Cell Cycle Arrest
20%
Cell Cycle Checkpoint
20%
Cell Viability
20%
Immunoblotting
20%
Antineoplastic Activity
20%
Protein Subunit
20%
Somatic Mutation
20%
Apoptosis Assay
20%
Targeted Therapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Uvea Melanoma
100%
Protein Kinase B
100%
B Raf Kinase
100%
N [3 (5 Chloro 1h pyrrolo[2,3 B]pyridine 3 Carbonyl) 2,4 Difluorophenyl]propanesulfonamide
70%
Selumetinib
60%
Mitogen Activated Protein Kinase Kinase Inhibitor
20%
Guanine Nucleotide Binding Protein
20%
Protein Kinase B Inhibitor
20%
8 [4 (1 Aminocyclobutyl)phenyl] 9 Phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) One
20%
Clinical Trial
10%
Western Blot
10%
Cell Viability
10%
Hexachlorophene
10%
Cutaneous Melanoma
10%
Apoptosis Assay
10%